The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Arbli is supplied as an peppermint-flavored oral suspension containing 10mg/mL of losartan potassium in 165mL bottles. The Food and Drug Administration (FDA) has approved Arbli ™, an oral ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers ...

Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will ...

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking and memory skills, according to a new study. The association was found in ...

AT-II-receptor antagonists include losartan, valsartan, irbesartan, candesartan, eprosartan, telmisartan, and tasosartan. Several clinical trials have demonstrated that AT-II-receptor antagonists ...